FineST: contrastive learning integrates histology and spatial transcriptomics for nuclei-resolved ligand-receptor analysis

L Lingyu Li T Tianjie Wang Z Zhuo Liang H Huajian Yu S Stephanie Ma (Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy, Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital) L Lequan Yu Y Yuanhua Huang

Abstract

Abstract Spatial transcriptomics (ST) has emerged as a powerful tool for analyzing cell-cell communication (CCC) across various biological processes, ranging from embryonic development to cancer progression. However, its limited resolution and high data sparsity hinder the detailed characterization of CCC patterns within complex tissues. Here, we introduce FineST , a deep contrastive learning model that leverages a histology foundation model to fuse ST and histology images, enabling Fine -grained S patial T ranscriptomics analysis. This approach facilitates precise nuclei segmentation, high-resolution RNA expression imputation, and the identification of intricate ligand-receptor interactions. Using both colorectal cancer VisiumHD and breast cancer Xenium datasets, we demonstrate that FineST significantly outperforms existing methods in high-resolution RNA imputation, cell type prediction, and CCC pattern discovery. With focused application to the Visium platform, FineST reveals novel biological insights into tumor-immune interactions across multiple cancer types, including invasive fronts in breast cancer, tertiary lymphoid structures in nasopharyngeal carcinoma, and PD-1 therapy resistance barriers in hepatocellular carcinoma. These findings highlight a new paradigm in ST analysis through the integration of readily available histology images.

Article Details

Volume / Issue Vol. 17, Issue 1
Published March 16, 2026
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (7)

L

Lingyu Li

T

Tianjie Wang

Z

Zhuo Liang

H

Huajian Yu

S

Stephanie Ma

Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy, Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital

L

Lequan Yu

Y

Yuanhua Huang